Mersana Therapeutics Inc (NASDAQ:MRSN) does about 1.41M shares in volume on a normal day but saw 1561327 shares change hands in the recent trading day. The company now has a market cap of 160.70M USD. Its current market price is $1.31, marking a decrease of -12.08% compared to the previous close of $1.49. The 52 week high reached by this stock is $6.28 whilst the lowest price level in 52 weeks is $1.07. The script in recent trading has seen the stock touch a high of $3 and a low of $3.
Mersana Therapeutics Inc (MRSN) has a 20-day trading average at $1.7038 and the current price is -79.14% off the 52-week high compared with 23.00% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.9206 and its 200-day simple moving average is $2.7979. If we look at the stock’s price movements over the week, volatility stands at 15.48%, which decreases to 11.21% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 33.52 to suggest the stock is neutral.
The consensus objective for the share price is $6.44, suggesting that the stock has a potential upside of 79.66% over the period. The median price target is 56.33% away from the current levels at $3.
5 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 19, 2024 when JP Morgan upgraded the stock to “Neutral” and issued a price target of $5. Wedbush also upgraded the stock to “Outperform” from Neutral on February 29, 2024 at a price target of $2-$7. Guggenheim upgraded its price target at $7.
Mersana Therapeutics Inc (MRSN) stock is down -9.34% over the week and -39.07% over the past month. Its price is -43.53% year-to-date and 11.02% over the past year.
Its 12-month price target is $3. To reach the target analysts have set, the stock logically needs to grow 79.66 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $3, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $3.
Outstanding shares total 120.71M with insiders holding 1.36% of the shares and institutional holders owning 94.57% of the company’s common stock. The company has a return on investment of -364.47% and return on equity of -213.33%. The beta has a value of 1.49. Price to book ratio is 19.07 and price to sales ratio is 5.37.
